仁和药业: 公司2024年度股东大会决议公告

Meeting Overview - The shareholder meeting of Renhe Pharmaceutical Co., Ltd. was held on May 23, 2025, with both on-site and online voting options available for shareholders [1][2] - A total of 434 shareholders (or their representatives) attended the meeting, representing 434,711,862 shares, which accounts for 31.0522% of the company's total share capital [2] Voting Results - Proposal 1: The 2024 Board of Directors' Work Report was approved [4] - Proposal 2: The 2024 Supervisory Board's Work Report received 432,613,137 votes in favor, representing 99.5172% of the total votes [4] - Proposal 3: The 2024 Annual Report and Summary was approved [4] - Proposal 4: The 2024 Financial Settlement Report was approved [4] - Proposal 5: The profit distribution plan for 2024 was approved, proposing a cash dividend of 1.50 yuan per 10 shares, totaling 1,399,938,234 shares as the base [4][5] - Proposal 6: The reappointment of the auditing firm for 2025 was approved [4] - Proposal 7: The use of self-owned funds for investment and financial management was approved [5] - Proposal 8: The election of non-independent directors for the 10th Board of Directors was approved with high support [5][6] - Proposal 9: The election of independent directors for the 10th Board of Directors was approved with significant majority votes [5][6] - Proposal 10: The election of non-employee representative supervisors was approved [6] Legal Compliance - The meeting complied with the relevant provisions of the Company Law and the Articles of Association, and the voting results were deemed legal and valid [6]